Pfizer Inc. [PFE] stock Upgrade by BofA Securities analyst, price target now $70



Pfizer Inc. [NYSE: PFE] gained 1.60% on the last trading session, reaching $55.72 price per share at the time. The company report on January 5, 2022 that Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States.

Transaction triggers total upfront payment to Biohaven of $500 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced that the parties have completed the collaboration transaction between the two companies. The transaction agreements, including Pfizer’s commercialization of rimegepant and zavegepant outside of the U.S., have become effective following the receipt of required regulatory approvals and the satisfaction of other customary conditions, and BHVN shares have been issued to Pfizer. Biohaven will continue to lead research and development globally and retain rights to the U.S. market.

Pfizer Inc. represents 5.61 billion in outstanding shares, while the company has a total market value of $307.81 billion with the latest information. PFE stock price has been found in the range of $54.63 to $55.77.

If compared to the average trading volume of 41.30M shares, PFE reached a trading volume of 27448586 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Pfizer Inc. [PFE]:

BofA Securities have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 05, 2022. While these analysts kept the previous recommendation, Bernstein raised their target price from $44 to $65. The new note on the price target was released on January 03, 2022, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another raise from $56 to $70, while Cowen kept a Outperform rating on PFE stock.

The Average True Range (ATR) for Pfizer Inc. is set at 2.05, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 4.44. The Price to Book ratio for the last quarter was 4.13, with the Price to Cash per share for the same quarter was set at 5.38. Price to Free Cash Flow for PFE in the course of the last twelve months was 14.56 with Quick ratio for the last quarter at 1.20.

Trading performance analysis for PFE stock

Pfizer Inc. [PFE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.64. With this latest performance, PFE shares gained by 8.40% in over the last four-week period, additionally plugging by 40.14% over the last 6 months – not to mention a rise of 50.07% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 50.07, with the RSI for the last a single of trading hit 45.95, and the three-weeks RSI is set at 52.89 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 52.86, while it was recorded at 55.47 for the last single week of trading, and 44.39 for the last 200 days.

Pfizer Inc. [PFE]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +21.52 and a Gross Margin at +71.21. Pfizer Inc.’s Net Margin is presently recorded at +16.67.

Return on Total Capital for PFE is now 8.14, given the latest momentum, and Return on Invested Capital for the company is 6.93. Return on Equity for this stock inclined to 11.05, with Return on Assets sitting at 4.34. When it comes to the capital structure of this company, Pfizer Inc. [PFE] has a Total Debt to Total Equity ratio set at 65.26. Additionally, PFE Total Debt to Total Capital is recorded at 39.49, with Total Debt to Total Assets ending up at 26.76. Long-Term Debt to Equity for the company is recorded at 60.48, with the Long-Term Debt to Total Capital now at 36.60.

Reflecting on the efficiency of the workforce at the company, Pfizer Inc. [PFE] managed to generate an average of $88,981 per employee. Receivables Turnover for the company is 5.03 with a Total Asset Turnover recorded at a value of 0.26.Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.40.

Pfizer Inc. [PFE]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to 19.50%.

>> 7 Top Picks for the Post-Pandemic Economy <<

An analysis of insider ownership at Pfizer Inc. [PFE]

There are presently around $204,455 million, or 67.60% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 459,942,303, which is approximately 0.82% of the company’s market cap and around 0.04% of the total institutional ownership; BLACKROCK INC., holding 410,828,305 shares of the stock with an approximate value of $22.89 billion in PFE stocks shares; and STATE STREET CORP, currently with $15.59 billion in PFE stock with ownership of nearly 0.443% of the company’s market capitalization.

Positions in Pfizer Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 1,402 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 180,919,555 shares. Additionally, 1,204 investors decreased positions by around 165,557,556 shares, while 271 investors held positions by with 3,322,860,398 shares. The mentioned changes placed institutional holdings at 3,669,337,509 shares, according to the latest SEC report filing. PFE stock had 182 new institutional investments in for a total of 27,633,749 shares, while 94 institutional investors sold positions of 9,614,691 shares during the same period.